These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31607313)

  • 1. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
    Shi R; Guo SQ; Chen YY; Liu S; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
    Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
    Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
    Zhang YP; Wu WZ; Cui GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Zhang Y; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):572-577. PubMed ID: 28810323
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
    Guo SQ; Shi R; Chen YY; Liu S; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):509-514. PubMed ID: 30998162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and Safety of Different Dosages of Decitabine in the Treatment of High-Risk Patients with Myelodysplastic Syndrome].
    Tong C; Ye F; Li NN; Wang H; Shu YN; Wang L; Zhang LN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1845-1850. PubMed ID: 34893121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
    Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
    Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
    Wu XF; Li TT; Sun L; Wang LJ; Ran XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
    Zhang JL; Cao YP; Li JG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of Decitabine Rigimen and Traditional Chemotherapy Regimen in Treatment of Patients with Intermediate or High-Risk Myelodysplastic Syndrome].
    Zhang QP; Han YS; Wan X; Sun GY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):197-201. PubMed ID: 29397843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
    Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
    Huang YQ; Zhang XY; Wu SX; Guo XZ; Pan JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1641-1646. PubMed ID: 29262890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
    Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
    Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparation of Clinical Efficacy between Two Regimens of Preexcitation Chemotherapy for MDS-RAEB Patients].
    Pan PJ; Luo ZQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):515-519. PubMed ID: 30998163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.